Browsing Tag
BCMA
4 posts
Gilead Sciences bets $2.2bn on immune reset with Ouro Medicines BCMAxCD3 bispecific acquisition
Gilead Sciences agrees to acquire Ouro Medicines for up to $2.175bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Read the full strategic analysis.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases
Candid Therapeutics begins Phase 1 trials of BCMA and CD20 T-cell engagers across five autoimmune diseases; institutional interest builds around TCE approach.
Keymed Biosciences’ CM336 shows sustained remission in AIHA patients after CAR-T failure
Keymed Biosciences’ CM336 delivers 6-month remission in AIHA post-CAR-T failure, with NEJM publication and bullish stock sentiment. Find out what’s next for the biotech.